郭靖　安曉雷　李曉賓　歐春影　許可

[摘要] 目的 分析尤瑞克林聯(lián)合醒腦靜治療急性腦梗塞對(duì)患者神經(jīng)功能的影響。 方法 方便選擇2017年2月—2018年2月，醫(yī)院神經(jīng)內(nèi)科收治的急性腦梗塞患者80例，按照入院順序分組，對(duì)照組、觀察組各入組40例，均給予基礎(chǔ)抗血小板、降血脂等基礎(chǔ)治療，對(duì)照組尤瑞克林，觀察組聯(lián)合醒腦靜。 結(jié)果 觀察組2周后、8周后、卒中90 d的NIHSS評(píng)分分別為（6.3±1.2）分、（4.0±2.1）分、（1.9±1.1）分低于對(duì)照組（7.7±1.5）分、（5.5±1.7）分、（3.1±1.0）分，差異有統(tǒng)計(jì)學(xué)意義（t=4.609、3.511、5.105，P=0.000、0.001、0.000<0.05）。觀察組與對(duì)照組2周后LPA分別為（2.2±0.7）μmol/L、（2.8±0.8）μmol/L低于治療前（3.7±1.1）μmol/L、（3.6±1.3）μmol/L（t=7.266、3.315，P=0.000、0.001）、觀察組低于對(duì)照組（t=3.570、P=0.001），觀察組與對(duì)照組卒中90 d的認(rèn)知功能量表評(píng)分分別為（27.4±2.6）分、（25.0±4.1）分高于2周時(shí)（24.1±2.4）分、（22.3±2.0）分（t=5.899、3.743，P=0.000、0.000）、觀察組高于對(duì)照組（t=3.127、0.002），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組認(rèn)知、精神相關(guān)并發(fā)癥發(fā)生率15.0%低于對(duì)照組37.5%，差異有統(tǒng)計(jì)學(xué)意義（χ2=5.230，P=0.022<0.05）。結(jié)論尤瑞克林聯(lián)合醒腦靜治療急性腦梗塞可以減輕神經(jīng)功能損傷。

[關(guān)鍵詞] 急性腦梗塞;神經(jīng)功能;尤瑞克林;醒腦靜

[中圖分類號(hào)] R743.3? ? ? ? ? [文獻(xiàn)標(biāo)識(shí)碼] A? ? ? ? ? [文章編號(hào)] 1674-0742（2019）07（a）-0106-03

Effect of Ureklin Combined with Xingnaojing on Neurological Function in Patients with Acute Cerebral Infarction

GUO Jing， AN Xiao-lei， LI Xiao-bin， OU Chun-ying， XU Ke

Department of Neurology， Xuzhou Central Hospital， Xuzhou， Jiangsu Province， 221000 China

[Abstract] Objective To analyze the effect of Ureklin combined with Xingnaojing on the neurological function of patients with acute cerebral infarction. Methods From February 2017 to February 2018， 80 patients with acute cerebral infarction admitted to the Department of Neurology of the hospital were convenient divided into two groups according to the order of admission. The control group and the observation group were each enrolled of 40 cases， all of which were given basic antiplatelet and blood lipid lowering treatment， the control group of Ureklin， the observation group combined with awakening brain. Results The NIHSS scores of the observation group were （6.3±1.2）points， （4.0±2.1）points， and （1.9±1.1）points lower than the control group （7.7±1.5）points， （5.5±1.7）points， （3.1±1.0） points after 2 weeks， 8 weeks， and 90 days of stroke， the difference was statistically significant （t=4.609， 3.511， 5.105， P=0.000， 0.001， 0.000<0.05）. After 2 weeks in the observation group and the control group， LPA was （2.2±0.7） μmol/L and （2.8±0.8） μmol/L， respectively， lower than （3.7±1.1） μmol/L and （3.6±1.3） μmol/L before treatment （t=7.266， 3.315， P=0.000， 0.001）， the observation group was lower than the control group （t=3.570， P=0.001）， and the cognitive function scale scores of the observation group and the control group were 90 days （27.4±2.6）points，（25.0±4.1）points points higher than 2 weeks （24.1 ± 2.4） points， （22.3±2.0） points （t=5.899， 3.743， P=0.000， 0.000）， the observation group was higher than the control group （t=3.127， 0.002）， the difference was statistically significant （P<0.05）. The incidence of cognitive and mental-related complications in the observation group was 15.0% lower than that in the control group （37.5%）， and the difference was statistically significant （χ2=5.230， P=0.022<0.05）. Conclusion Ureklin combined with Xingnaojing can reduce neurological damage by treating acute cerebral infarction.